血清中microRNA在预测肝细胞癌患者预后作用的研究探讨

doi:10.11904/j.issn.1002-3070.2016.02.010

摘要/Abstract

摘要： 肝细胞癌(Hepatocellular carcinoma,HCC)是最为常见的恶性肿瘤之一,经肝动脉灌注栓塞(Transcatheter arterial chemoembolization,TACE)是一种新的治疗HCC的方法,是目前不能手术的HCC患者的标准治疗方法。MicroRNA(miRNA)是一种微小的非编码RNA,研究已经发现miRNA与肿瘤的预后有关,并且证实部分miRNA能够作为生物学标志物在HCC患者接受TACE治疗前进行预测,本篇综述对miRNA作为生物学标志物在接受TACE治疗的肝细胞癌患者预后的预测方面研究做一归纳分析。

关键词: 肝细胞癌, 肝动脉灌注射栓塞, miRNA, 预后, 生物学标志物

Abstract: Hepatocellular carcinoma(HCC)is one of the most malignant tumors,transcatheter arterial chemoembolization(TACE)is a new treatment for HCC,which is currently considered as the standard care for patients with unresectable HCC.MicroRNAs(miRNAs),a class of small non-coding RNAs,the correlations within miRNA dictions and tumor prognosis have been documented,and a part of miRNAs has been proposed as biomarkers to reliably predict the outcomes before HCC patients being treated with TACE.

Key words: HCC, miRNA, TACE, Prognosis, Biomarker

中图分类号:

R735.7

王野, 畅智慧, 赵相轩综述, 刘兆玉审校. 血清中microRNA在预测肝细胞癌患者预后作用的研究探讨[J]. 实用肿瘤学杂志, 2016, 30(2): 142-145.

WANG Ye, CHANG Zhihui, ZHAO Xiangxuan, LIU Zhaoyu. The prognosis predicting effect of serum microRNA in the patients with hepatocellular carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 142-145.

参考文献

1 Yang JD,Roberts LR.Epidemiology and management of hepatocellular carcinoma[J].Infect Dis Clin North Am,2010,24(4):899-919.
2 Lee JO,Lee KW,Oh DY,et al.Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma[J].Ann Oncol,2009,20(8):1402-1407.
3 Cui LM,Hu Y,Bai B,et al.Serum miR-335 level is associated prognosis in patients with hepatocellular carcinoma[J].Cell Physiol Biochem,2015,37(1):276-283.
4 He L,Hannon GJ.MicroRNAs:small RNAs with a big role in gene regulation[J].Nat Rev Genet,2004,5(7):522-531.
5 Esteller.Non-coding RNAs in human disease[J].Nat Rev Genet,2011,12(12):861-874.
6 Ling H,Fabbri M,Calin GA.et al.MicroRNAs and other non-coding RNAs as targets for anticancer drug development[J].Nat Rev Drug Discov,2013,12(11):847-865.
7 Ueda T,Volinia S,Okumura H,et al.Relation between microRNA expression and progression and prognosis of gastric cancer:a microRNA expression analysis[J].Lancet Oncol,2010,11(2):136-146.
8 Zhou J,Yu L,Gao X,et al.Plasma microrna panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J].J Clin Oncol,2011,29(36):4781-4788.
9 Cho HJ,Kim JK,Nam JS,et al.High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus related hepatocellular carcinoma who undergoing radiofrequency ablation[J].Clin Biochem,2015,48(16-17):1073-1078.
10 Chen L,Chu FH,Cao YL,et al.Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma[J].Tumor Biol,2015,36(10):7439-7447.
11 Wang Y,Toh HC,Chow P,et al.MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms[J].FASEB J,2012,26(7):3032-3041.
12 Zhuang LP,Meng ZQ.Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival[J].Bio Med Res Int,2015,2015:731781.
13 Selcuklu SD,Donoghue MA,Spillane C,et al.MiR-21 as a key regulator of oncogenic processes[J].Biochem Soc T,2009,37(Pt 4):918-925.
14 Zhu S,Wu H,Wu F,et al.MicroRNA-21 targets tumor suppressor genes in invasion and metastasis[J].Cell Res,2008,18(3):350-359.
15 Qian B,Katsaros D,Lu L,et al.High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1[J].Breast Cancer Res Tr,2009,117(1):131-140.
16 Gao W,Shen H,Liu L,et al.MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis[J].J Cancer Res Clin,2011,137(4):557-566.
17 Dillhoff M,Liu J,Frankel W,et al.MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival[J].J Gastrointest Surg,2008,12(12):2171-2176.
18 Ying Q,Liang L,Guo W,et al.Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein inhepatocellular carcinoma[J].Hepatology,2011,54(6):2064-2075.
19 Zhan MX,Li Y,Hu BS,et al.Serum MicroRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].Lab Invest,2014,25(8):1279-1287.
20 Hung CS,Liu HH,Liu JJ,et al.MicroRNA-200a and-200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transitionmarkers[J].Ann Surg oncol,2013,20(3):360-368.
21 Dhayat SA,Mardin WA,Kohler G,et al.The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma[J].J Surg Oncol,2014,110(4):430-438.
22 Liu M,Liu J,Wang L,et al.Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival[J].PLoS One,2014,9(10):e109347.
23 Zhang J,Tu Q,Bonewald LF,et al.Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1[J].J Bone Miner Res,2011,26(8):1953-1963.
24 Cao J,Cai J,Huang D,et al.miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w[J].Oncol Rep,2013,30(2):701-706.
25 Peng HH,Zhang YD,Gong LS,et al.Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma[J].Onco Targets Ther,2013,6(5):1625-1630.
26 Zheng J,Lin Z,Dong P,et al.Activation of hepatic stellate cells is suppressed by microRNA-150[J].Int J Mol Med,2013,32(1):17-24.
27 Zhang J,Luo N,Luo Y,et al.microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb[J].Int J Oncol,2012,40(40):747-756.
28 Yu FJ,Lu ZQ,Chen BC,et al.microRNA-150:a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma[J].Diagn Pathol,2015,10(1):129-138.
29 Tian S,Huang S,Wu S,et al.MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3′ untranslated region[J].Biochem Biophys Res Commun,2010,396(2):435-439.
30 Liu JB,Yan JC,Zhou CC,et al.miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma[J].Tumor Biol,2015,36(8):219-225.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.
[4]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[5]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[6]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[7]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[8]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[9]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[10]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[14]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[15]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.